Phaseline

Targets › ROR1

ROR1 (Inactive tyrosine-protein kinase transmembrane receptor ROR1): drug programs, companies and trials

4 programs from 4 companies in 11 trials: 5 Phase 2, 5 Phase 1, 1 Phase 3; Oncology; next expected readout Sep 2027.

Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo. Receptor for ligand WNT5A which activates downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling. (UniProt, Q01973)

Open in Phaseline: the race on ROR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck & Co. (MSD)Cirmtuzumab (MK-2140)
Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor
ROR1Phase 3Diffuse Large B-Cell Lymphoma; DLBCL; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large B-Cell, Diffuse (DLBCL) …Sep 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2101 for Injection
anti-ROR1 antibody-drug conjugate
ROR1Phase 1Advanced Hematologic MalignanciesJun 2028
Shanghai EpimAb BiotherapeuticsEMB-07
Bispecific antibody targeting CD3 and ROR1
CD3, ROR1Phase 1Combination TherapyJun 2028
NEOK BioNEOK001
B7-H3 and ROR1 targeting bispecific antibody-drug conjugate
B7H3, ROR1Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsJan 2029

Conditions

Chronic Lymphocytic Leukemia (2) Diffuse Large B-Cell Lymphoma (1) DLBCL (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Large B-Cell, Diffuse (DLBCL) (1) Urothelial Carcinoma (1) B-cell Acute Lymphoblastic Leukemia (1) Locally Advanced (Unresectable) or Metastatic Solid Tumors (1) Advanced Hematologic Malignancies (1) Combination Therapy (1)

Modalities

mixed (2), small molecule (2)

Companies

Merck & Co. (MSD) (1) NEOK Bio (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1) Shanghai EpimAb Biotherapeutics (1)

Related targets

B7H3 (1) CD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.